Oramed Pharmaceuticals Inc.
ORMP
$3.65
$0.010.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -43.95% | 189.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -35.49% | 133.70% | |||
| Operating Income | 35.49% | -133.70% | |||
| Income Before Tax | 404.64% | -83.52% | |||
| Income Tax Expenses | 5,350.00% | -101.92% | |||
| Earnings from Continuing Operations | 282.76% | -79.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -100.00% | |||
| Net Income | 282.76% | -79.32% | |||
| EBIT | 35.49% | -133.70% | |||
| EBITDA | 35.68% | -135.48% | |||
| EPS Basic | 317.79% | -80.60% | |||
| Normalized Basic EPS | 180.16% | -300.89% | |||
| EPS Diluted | 304.62% | -80.10% | |||
| Normalized Diluted EPS | 177.83% | -311.87% | |||
| Average Basic Shares Outstanding | -0.32% | -2.04% | |||
| Average Diluted Shares Outstanding | 2.61% | -4.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||